Comparative Pharmacology
Head-to-head clinical analysis: MEDIHALER ERGOTAMINE versus MIGRANAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEDIHALER ERGOTAMINE versus MIGRANAL.
MEDIHALER ERGOTAMINE vs MIGRANAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergotamine is a serotonin (5-HT1B/1D) receptor agonist with additional affinity for 5-HT2, dopamine D2, and alpha-adrenergic receptors. It causes vasoconstriction of cranial blood vessels and inhibits neurogenic inflammation.
MIGRANAL (dihydroergotamine mesylate) is an ergot alkaloid with agonist activity at serotonin 5-HT1D and 5-HT1B receptors, leading to vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission, thereby aborting migraine attacks.
One inhalation (0.36 mg ergotamine) at onset of migraine; may repeat after 5 minutes if needed, up to 6 inhalations per attack and 15 per week.
1 mg intramuscularly at onset of migraine headache; may repeat after 1 hour if needed. Maximum: 2 mg per day and 4 mg per week.
None Documented
None Documented
The terminal elimination half-life is approximately 2 hours for the initial phase, followed by a prolonged terminal phase of 21-30 hours due to slow release from tissue binding sites. This long terminal half-life contributes to the risk of accumulation and toxicity with frequent dosing.
Terminal elimination half-life ranges from 7 to 10 hours (mean 8.5 hours). Prolonged in renal impairment.
Ergotamine is extensively metabolized in the liver. Approximately 90% of the dose is excreted as metabolites in the bile/feces, with less than 3% excreted unchanged in urine.
Primarily hepatic metabolism followed by renal excretion. Approximately 10% excreted unchanged in urine; fecal excretion accounts for <1%.
Category D/X
Category C
Ergot Alkaloid
Ergot Alkaloid